Instead of transactivating HSPA5 in OS cells 7, 8, ATF4 negatively regulates GRP78 transcription in BTZ-resistant OS cells, thus reinforcing the therapeutic effect of BTZ by the dual targeting of GRP78 and RET in the context of osteosarcoma chemoresistance (Figure 8E). Here, CASC3 is linked to osteosarcoma.